OR WAIT null SECS
Recipharm and Laccure AB signed a commercial collaboration for the manufacture and delivery of Laccure’s bacterial vaginosis treatment.
On Dec. 1, 2016 Recipharm announced that it has entered a commercial collaboration with Laccure AB for the manufacture and delivery of Laccure Pessary, a non-prescription vaginal tablet for the treatment of bacterial vaginosis. Laccure Pessary will be manufactured, packaged, and distributed globally from Recipharm’s facility in Karlskoga that specializes in the production of semi-solid products. Recipharm and Laccure AB have now signed an agreement for commercial production of Laccure Pessary, and the exact date for the launch will be announced in 2017. Laccure Pessary is based on a patented substance that releases lactic acid.